On August 19, MEDBOT-B fell 5.16% in regular trading, trading at HK$23.54/share, with turnover of HK$44.26 million. The Health Care Equipment sector where MEDBOT-B belongs saw broad-based weakness, with MICROPORT down 3.75%, ANGELALIGN down 2.89%, STAR SPORTS MED down 15.34%, TH MEDICAL-B down 9.85%, and EDGE MEDICAL-B down 2.70%.

The decline comes amid lingering concerns over parent company MicroPort Medical's debt situation. MicroPort Medical recently disclosed that its continuing operations recorded a net loss of up to US$50 million for H1, weighed down by approximately US$43 million in financing costs, foreign exchange fluctuations, and convertible loan fair value adjustments. The company faces a performance commitment deadline requiring full-year profit of US$90 million, intensifying investor scrutiny across the MicroPort ecosystem.

MEDBOT-B itself previously issued a positive profit alert, projecting its first-ever half-year profit of RMB 28-40 million for H1, with revenue surging 200%-230% year-over-year. The company's board is scheduled to formally approve interim results on August 27.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)